ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1361

Disease Burden Is Comparable in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Joachim Sieper1, Désirée van der Heijde2, Dirk Elewaut3, Aileen L. Pangan4 and Jaclyn K. Anderson4, 1Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, 4Abbott Laboratories, Abbott Park, IL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Chronic back pain and functional impairment are disease characteristics common to all patients (pts) with axial spondyloarthritis (SpA), regardless of the presence of radiographic sacroiliitis in ankylosing spondylitis (AS) or its absence in non-radiographic axial SpA (nr-axSpA). This analysis compares baseline disease characteristics of pts with nr-axSpA and AS in registries and randomized clinical trials (RCT) with adalimumab (ADA).

Methods: Registry data in this analysis include the German SpA Inception Cohort (GESPIC)1 that compared pts with AS by modified New York criteria (divided into >5 yrs and ≤5 yrs) and nr-axSpA (≤5 yrs) meeting modified ESSG criteria and a prospective cohort of TNF-naïve SpA pts meeting ASAS criteria for axial SpA.2 ADA RCT data were derived from the ATLAS study3 in AS pts, and the ABILITY-14 and Haibel5 studies in nr-axSpA pts. Pts in RCTs were selected based on a pre-specified level of disease activity and inadequate response to non-steroidal anti-inflammatory drugs.

Results: Mean age was similar in nr-axSpA and AS pts, ranging from 36-42 yrs (table). A higher proportion of AS pts had elevated CRP as compared to nr-axSpA pts and gender differences were observed, with nr-axSpA pts being predominantly female and AS pts primarily male. Symptomatic pts with nr-axSpA and AS often went undiagnosed for years. Similar levels of disease activity as measured by the BASDAI, pain scores, and pt and physician global assessments of disease activity were seen between nr-axSpA and AS pts in registries and RCTs, with levels of disease activity generally higher in RCT pts due to minimum levels of baseline disease activity required for study eligibility.

Conclusion: Registry and clinical trial data demonstrate that both nr-axSpA and AS patients have comparable burden of disease. These findings suggest that all patients with axial spondyloarthritis can present with similar debilitating signs and symptoms requiring treatment regardless of the extent of radiographic damage.

 

Table. nr-axSpA and AS baseline disease characteristics

 

Registries

RCTs

GESPIC

Kiltz

ATLAS

ABILITY-1

Haibel

All AS

AS ≤5 yrs

nr-axSpA ≤5 yrs

AS

nr-axSpA

AS

nr-axSpA

nr-axSpA

N=236

N=119

N=226

N=56

N=44

N=315

N=185

N=46

Age, yrs

35.6

36.1

36.1

41.2

39.1

42.2

38.0

37.5

Female, %

36.0

34.5

57.1

23.2

68.2

25.1

54.6

54.3

HLA-B27 +, %

88.2

73.1

74.7

89.1

86.4

78.7

75.1

67.4

Symptom duration, yrs

5.2

3.0

2.6

12.8

9.4

–

10.1

7.5

Duration since diagnosis, yrs

2.8

1.7

1.7

7.5

5.0

10.6

2.9

–

BASDAI, 0–10

4.0

4.0

3.9

4.2

3.6

6.3

6.5

6.3

Abnormal CRP, %

51.9

49.6

29.8

69.1

29.5

67.6

35.7

37.8

Total back pain, VAS 0–10

–

–

–

–

–

6.5

6.9

–

Total pain, VAS 0–10

5.0

4.8

4.8

4.7

4.0

–

6.8

7.2

PtGA of disease activity, VAS 0–10

5.0

5.0

4.9

4.6

4.0

6.3

6.8

6.6

PhGA of disease activity, VAS 0–10

4.5

4.4

3.6

3.5

2.7

5.7

5.7

5.9

Values are the mean unless otherwise indicated. AS, ankylosing spondylitis; BASDAI, Bath AS Disease Activity Index; CRP, C-reactive protein; nr-axSpA, non-radiographic axial spondyloarthritis; PhGA, physician global assessment; PtGA, patient global assessment; RCT, randomized clinical trial; VAS, visual analog scale.

References

1. Arthritis Rheum2009;60:717.

2. Arthritis Care Res2012. doi:10.1002/ACR.21688.

3. Arthritis Rheum2006;54:2136.

4. Abstract 2486A. Arthritis Rheum2011;63(Suppl):S970.

5. Arthritis Rheum 2008;58:1981.


Disclosure:

J. Sieper,

Abbott, Merck, Pfizer, UCB,

2,

Abbott, Merck, Pfizer, UCB,

5,

Abbott, Merck, Pfizer, UCB,

8;

D. van der Heijde,

Abbott Laboratories; Amgen; AstraZeneca; BMS; Centocor: Chugai; Eli-Lilly; GSK; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Schering-Plough; UCB; Wyeth,

5,

Abbott Laboratories; Amgen; AstraZeneca; BMS; Centocor: Chugai; Eli-Lilly; GSK; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Schering-Plough; UCB; Wyeth,

2,

Imaging Rheumatology,

4;

D. Elewaut,

Abbott Laboratories,

2,

Abbott Laboratories,

8;

A. L. Pangan,

Abbott Laboratories,

3,

Abbott Laboratories,

1;

J. K. Anderson,

Abbott Laboratories,

3,

Abbott Laboratories,

1.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-burden-is-comparable-in-patients-with-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology